Skip to main content

Phase 3 Readout

LLY: Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Ef

July 28, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date
July 28, 2026
Company
ELI LILLY & Co (LLY)
BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout

Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Ef

LLY overview →
Indication
Atopic Hand and Foot Dermatitis

Other upcoming events for LLY

Phase 2 StartPhase 2 Start: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safet
Phase 1 StartPhase 1 Start: A Placebo-Controlled, Single- and Multiple-Ascending Dose, Phase 1 Study to Evaluate the Safety, Tol
Phase 1 StartPhase 1 Start: A Master Protocol for Phase 1 Clinical Trials of Multiple Amyloid-Targeting Therapies for the Treatm
Phase 3 ReadoutPhase 3 Topline: Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharm
Phase 1 StartPhase 1 Start: A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics o